Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AltheaDx, Inc.
Dealmaking Quarterly Statistics, Q2 2022
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
Arcturus Founder Reinstated As CEO As Settlement Ends Four-Month Feud With Former Board
The unexpected firing of Arcturus CEO Joseph Payne kicked off a bitter public battle for control of the RNA therapeutics firm after a reverse merger with Alcobra in November. The dispute now settled, the new board has reinstated Payne at Arcturus' helm.
Permira Inks Deal To Buy Orthopedics Firm Corin
Permira has signed a deal to acquire a majority stake in orthopedics group Corin from a group of investors for an undisclosed price.
Epigenomics, RainDance, and Brightree name new leadership, and more personnel news from around the industry.
- Laboratory Testing Services
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.